ADAM17 and COVID-19: While ADAM17 does not facilitate SARS‐CoV‐2 entry,3, 4 the protease may mediate COVID‐19 severity via pathological activation through intracellular SARS‐CoV‐2 accumulation, leading to enhanced ADAM17 activity.